Patents by Inventor Anna Bernardi

Anna Bernardi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260008761
    Abstract: Disclosed is a process for the preparation of taxanes esterified with octadecanedioic acid which comprises reacting a taxane with an octadecanedioic acid protected in one of the two carboxyl groups and protected with a group removable by catalysis with transition metals.
    Type: Application
    Filed: September 29, 2022
    Publication date: January 8, 2026
    Applicant: Indena S.P.A.
    Inventors: Vincenzo Rositano, Luca Senaldi, Andrea Gambini, Anna Bernardi
  • Publication number: 20250066411
    Abstract: The present invention relates to new glycomimetic molecules which selectively bind to the L-SIGN receptor, finding application in the medical field and, in particular, in the prevention and treatment of viral infections, in the immunotherapy of liver tumors and in the treatment of immune diseases.
    Type: Application
    Filed: October 24, 2024
    Publication date: February 27, 2025
    Applicants: UNIVERSITA’ DEGLI STUDI DI MILANO, UNIVERSITÉ GRENOBLE ALPES, COMMISSARIAT A L’ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Anna BERNARDI, Sara POLLASTRI, Clara DELAUNAY, Michel THÉPAUT, Franck FIESCHI, Gianluca CAVAZZOLI
  • Patent number: 11214543
    Abstract: The present invention relates to a process for the preparation of Lenvatinib of formula (I) from 4-amino-3-chloro-phenol and 4-chloro-7-methoxyquinoline-6-carboxamide.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: January 4, 2022
    Assignee: Indena S.P.A.
    Inventors: Luca Senaldi, Pietro Allegrini, Daniele Ciceri, Anna Bernardi
  • Publication number: 20210246107
    Abstract: The present invention relates to a process for the preparation of Lenvatinib of formula (I) from 4-amino-3-chloro-phenol and 4-chloro-7-methoxyquinoline-6-carboxamide.
    Type: Application
    Filed: September 3, 2019
    Publication date: August 12, 2021
    Applicant: Indena S.P.A.
    Inventors: Luca Senaldi, Pietro Allegrini, Daniele Ciceri, Anna Bernardi
  • Patent number: 10336707
    Abstract: The present invention relates to novel heterocyclic derivatives having general formula (I) and their therapeutic use for diseases such as cancer, inflammation, pain, autoimmune diseases or neurodegenerative diseases like Alzheimer's or Parkinson's disease that can be treated by modulation of certain protein kinases. Compounds of formula (I) can be used for treatment of patients who do not respond to kinase inhibition therapy that comprises currently available medications.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: July 2, 2019
    Assignees: EUDENDRON S.R.L., UNIVERSITA' DEGLI STUDI DI MILANO
    Inventors: Mauro Angiolini, Fabio Zuccotto, Anna Bernardi, Francesco Airaghi
  • Publication number: 20180118691
    Abstract: The present invention relates to novel heterocyclic derivatives having general formula (I) and their therapeutic use for diseases such as cancer, inflammation, pain, autoimmune diseases or neurodegenerative diseases like Alzheimer's or Parkinson's disease that can be treated by modulation of certain protein kinases. Compounds of formula (I) can be used for treatment of patients who do not respond to kinase inhibition therapy that comprises currently available medications.
    Type: Application
    Filed: December 14, 2015
    Publication date: May 3, 2018
    Inventors: Mauro Angiolini, Fabio Zuccotto, Anna Bernardi, Francesco Airaghi